Roche Holding (RHHBY – Analyst Report) announced that the FDA has granted accelerated approval to its cancer immunotherapy drug, Tecentriq (atezolizumab), for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC), who experienced disease progression during or after platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
{iframe}http://www.zacks.com/stock/news/217974/roche-gets-accelerated-approval-for-immunotherapy-drug{/iframe}